Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TAGAMET HB LAUNCH PLAN INCLUDES MAILINGS TO 460,000 HEALTH PROFESSIONALS

This article was originally published in The Tan Sheet

Executive Summary

TAGAMET HB LAUNCH PLAN INCLUDES MAILINGS TO 460,000 HEALTH PROFESSIONALS to announce the availability of the OTC cimetidine product and to provide information on the drug's labeled indications, dosing, warnings and precautions, SmithKline Beecham Consumer Healthcare Products President-North America Jack Ziegler told a joint meeting of FDA's Nonprescription Drugs and Gastrointestinal Drugs Advisory Committees on July 27. "Immediately upon approval" of Tagamet HB, mailgrams will be sent to 300,000 physicians, 110,000 pharmacists and 50,000 allied health professionals, Ziegler said.

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS083079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel